To launch Level II Applet click here.

From DNAPrint.com:
DNAPrintTM genomics, Inc. is a genomics science company focused on the sale of unique proprietary genetic testing
Products and services. The Company's core patented and proprietary technologies for efficiently targeting single nucleotide polymorphisms ("SNPs") enable us to provide novel predictive genetic tests at a significant cost advantage over our competitors. DnaPrint.com

Source: DNAPrint genomics, Inc. DNAPrint genomics Launches Radio Advertising Campaign for ANCESTRYbyDNA on 1010 WINS, a Popular All-News Media Outlet in New York City SARASOTA, Fla., Sept. 29, 2005 (PRIMEZONE) -- DNAPrint(tm) genomics, Inc. (OTCBB:DNAG) today announced that it has launched a radio advertising campaign for its ANCESTRYbyDNA(tm) consumer product with 60-second spots being broadcast by 1010 WINS, a popular all news station serving the New York City Metropolitan area. "With the growing popularity for family ancestry research, DNAPrint genomics is taking its message to consumers through a well-known mass-market media outlet," stated President and Chief Executive Officer Richard Gabriel. "Our ANCESTRYbyDNA genome-based test that determines genetic heritage is an excellent tool for individuals or groups interested in learning about their ancestry and lineage." The advertising spots are being aired by 1010 WINS at various times throughout the day, About DNAPrint genomics, Inc. DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS(tm), RETINOME(tm), ANCESTRYbyDNA(tm) and EURO-DNA(tm). Forward Looking Statements All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. The DNAPrint genomics logo can be found at: http://www.primezone.com/newsroom/prs/?pkgid=1949 CONTACT: DNAPrint genomics Richard Gabriel President and CEO 941-366-3400 The Wall Street Group, Inc. Ron Stabiner 212-888-4848